SFS
CRVS icon

Sowell Financial Services’s Corvus Pharmaceuticals CRVS Stock Holding History

Sowell Financial Services’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Sell
15,000
-2,000
-12% -$31.9K 0.01% 995
2025
Q4 		$131K Buy
17,000
+5,000
+42% +$39.4K ﹤0.01% 1072
2025
Q3 		$88.4K Hold
12,000
– – ﹤0.01% 1043
2025
Q2 		$48K Hold
12,000
– – ﹤0.01% 1027
2025
Q1 		$38.2K Buy
+12,000
New +$56.5K ﹤0.01% 997

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sowell Financial Services's CRVS Position: Q1 2026 in Review

Sowell Financial Services reduced its Corvus Pharmaceuticals (CRVS) stake by 12% in Q1 2026, selling an estimated $31.9K and leaving 15,000 shares worth $219K. The position accounts for 0.01% of the portfolio, ranked #995.

Sowell Financial Services first reported a position in CRVS in Q1 2025 and has held it in 5 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Sowell Financial Services held 15,000 shares of Corvus Pharmaceuticals worth $219K as of Q1 2026.
  • Sowell Financial Services sold 2,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $31.9K.
  • Corvus Pharmaceuticals made up 0.01% of Sowell Financial Services's portfolio in Q1 2026, its #995 holding.
  • Sowell Financial Services first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Sowell Financial Services's 13F filing for Q1 2026, filed 20 Apr 2026.